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The primary aim was to determine if sequential administration of oxytocin and nitroglycerin is eﬀective for management of
retained placenta when performed by obstetricians with no experience of the method. Secondary aims were to examine possible
adverse eﬀects of nitroglycerin. One hundred and ﬁve women with retained placenta were randomly selected to receive either
1mg nitroglycerin or placebo tablets sublingually if intravenous oxytocin had failed to expel the placenta. At two of the hospitals
some of the midwives were familiar with the use of nitroglycerin. The other midwives and all the participating obstetricians had
no clinical experience of the method. In the treatment group, detachment of placenta following nitroglycerin occurred in 37.3%
of the women compared to 20.4% in the placebo group (P = 0.056). In the two hospitals with some experience of the method,
placenta was removed in 9 of 19 (47.4%) women in the nitroglycerin group compared to 3 of 17 (15.0%) women in the placebo
group. No adverse eﬀects of clinical importance were registered. Although the diﬀerence between the two groups did not reach
statistical signiﬁcance, the higher success rate in the two hospitals with some experience could indicate that clinical experience is
of importance in order to achieve placental detachment.
1.Introduction
Retained placenta complicates up to 2.0–3.3% of all vaginal
deliveries [1, 2]. The most common cause of retained
placenta has been shown to be a failure of retroplacental
myometrial contractions [3]. Without immediate treatment,
women are at high risk of hemorrhage. The delivery of
oxytocin to the retroplacental myometrium via the umbilical
vein or intravenously is often applied to induce myome-
trial contractions and placental detachment. The WHO
guidelines for management of postpartum hemorrhage and
retained placenta recommend injection of saline-diluted
oxytocin into the umbilical vein [4]. However, a recently
published large randomized study concluded that this
method has no clinically signiﬁcant eﬀect [5]. Thus, manual
removal of the placenta under general or regional anesthesia
is usually needed.
Alternatively, when oxytocin fails, it has been shown that
the sequential administration of oxytocin and sublingual
nitroglycerin is eﬃcient for the management of retained
placenta [6, 7]. Nitroglycerin relaxes smooth muscle cells by
releasing nitric oxide and is regularly used to induce prompt
uterine relaxation in cases of obstetric emergency [8].
A recent Cochrane review concluded that sublingual
nitroglycerin seems to both reduce the need for manual
removal of placenta and blood loss during the third stage
of labour when compared to placebo [9]. However, it was
also emphasized that further trials are needed to conﬁrm its
clinical role and safety.
A very high success rate for management of retained
placenta was reported following sequential administration of2 Obstetrics and Gynecology International
oxytocin and nitroglycerin when performed by obstetricians
who were experienced in this method [6, 7]. However, in an
everyday clinical setting we noticed that many obstetricians
with little or no experience in this method often failed
in their attempts to remove the placenta. The primary
aim of the present study was therefore to determine if
oxytocin in combination with nitroglycerin is eﬀective in
the management of retained placenta when performed
by inexperienced obstetricians. Secondary aims were to
examine hemodynamic eﬀects, blood loss, and side eﬀects
following sublingual administration of nitroglycerin and to
identify factors that could have a negative eﬀect on placental
detachment.
2.MaterialsandMethods
This was a prospective double-blind randomized controlled
multicenter study that was carried out at ﬁve Swedish
hospitals between October 2008 and July 2010. Two of the
hospitals (hospitals A and B) were university hospitals with
approximately4100and6400deliveriesperyear,respectively,
while the three other hospitals were referral hospitals (hospi-
tals C, D, and E) with 2100 to 3200 deliveries per year. At the
two university hospitals some of the midwives were familiar
with the use of nitroglycerin for management of retained
placenta.Noneofthemidwivesatthethreeotherhospitalsor
any of the obstetricians involved in the study had any clinical
experience of the method. All participating obstetricians
and midwives received written information about the study.
Inclusion criteria were uncomplicated singleton pregnancy
with spontaneous vertex delivery of a healthy child at term.
Exclusion criteria were serious maternal disease, maternal
age less than 18 years, blood loss more than 600mL, uterine
malformation, or suspected placental accreta. Thus, women
with previous Cesarean section were not excluded from
participating in the study. The study was approved by the
medical ethics committees of the participating hospitals.
All pregnant women who planned to give birth at any of
the ﬁve hospitals received written as well as oral information
about the study several weeks before expected delivery.
According to the study protocol, if the placenta remained
undelivered30minutesafterchildbirth,aslowpushof10IU
(16.6µg) oxytocin (Syntocinon, Novartis, T¨ aby, Sweden) was
administered intravenously to promote uterine contractions
and placental detachment. Five minutes after injection of
oxytocin, controlled cord traction was performed once more
to facilitate placental delivery. If the placenta remained
undelivered 40 minutes after childbirth the women were
asked to participate in the study. They were also informed
a b o u tp o s s i b l es i d ee ﬀects of nitroglycerin. In addition,
intravenous administration of Ringer-acetate was instituted
routinely as a prophylactic measure in case of postpartum
hemorrhage and all the women were hemodynamically
monitored.
Randomization was carried out at a ratio of 1:1
by blocks of 4 (http://www.randomization.com/), and the
allocation was performed by means of numbered opaque,
sealed envelopes. A nurse who did not participate in the
remainder of the study handed out the study medication as
needed.
Following informed consent, the women were allocated
to either of the two groups: (1) 1mg of nitroglycerin tablets
(two 0.5mg tablets) Nitromex, Alpharma AB, Stockholm,
Sweden) or (2) two placebo tablets. The tablets were
administered sublingually approximately 50 minutes after
childbirth. Neither the obstetrician nor the participating
women were aware of the agent administered. Five minutes
after administration of nitroglycerin or placebo tablets,
gentle persistent cord traction was performed once more
for a maximum duration of ﬁve minutes. The procedure
was regarded as successful if the placenta was delivered in
the delivery room without the need of operative manual
removal under either regional (epidural or spinal) or general
anesthesia.
Maternal blood pressure and pulse rate were measured
prior to administration of nitroglycerin or placebo tablets.
T h e s em e a s u r e m e n t sw e r er e p e a t e dﬁ v em i n u t e sa sw e l la s
15 minutes after administration of the tablets for assessment
of possible hemodynamic eﬀects caused by nitroglycerin.
In addition, total blood loss during the third stage of
delivery was registered. Blood loss was assessed by weight
and visual estimation, and in some cases also combined with
measurement of collected blood poured into a measuring
jar. The women also completed a questionnaire regarding
p o s s i b l es i d ee ﬀects of nitroglycerin. In addition, medical
records were routinely checked in order to identify factors
that could adversely aﬀect the outcome of the procedure.
2.1. Statistics. As a m p l es i z eo f1 1 4w o m e n( 5 7i ne a c h
group) was calculated to yield a power of 90% at the 5%
signiﬁcance level when assuming a success rate of 50%
in the treatment group compared to 20% in the placebo
group. Some withdrawals from the study were expected
and therefore a sample size of 120 women was decided.
Continuous variables between the treatment group and the
placebo group were analyzed by using the Mann-Whitney
U test, while the Chi-square test was used for analysis of
dichotomous variables. For comparison between groups the
Mantel-Haenszel Chi-square test was used for ordered cate-
gorical variables and the Chi-square test was used for non-
ordered categorical variables. The 95% conﬁdence interval
was used for assessment of relative risk for dichotomous
variables. Change from baseline variables within treatment
groups was analyzed by using the Wilcoxon signed rank
test. For categorical variables n (%) is presented and for
continuous variables Mean, SD, median, min, and max are
presented. Signiﬁcance tests were two-sided and conducted
at 5% signiﬁcance level.
3. Results
One hundred twenty women agreed to participate in the
study. However, two women were excluded since only one
tablet (0.5mg) of nitroglycerin by mistake was administered.
In addition, spontaneous placental detachment occurred in
three women immediately before administration of tablets,Obstetrics and Gynecology International 3
while in one case umbilical cord disruption occurred before
administration of tablets. Furthermore, in nine women
surgical removal of placenta was performed initially due to
thepreferenceoftheobstetricianondutydespitethefactthat
the women had given their informed consent to participate.
Thus, the total number of patients in the intention to treat
group (ITT) was 111 (all randomized patients, including
4 patients who did not receive study medication and 2
patients who only received 0.5mg nitroglycerin), and the
number of patients in the per protocol group (PP) was 105
(randomized patients who all received study medication, i.e.,
1mg nitroglycerin or placebo tablets).
There were no diﬀerences between the two groups
regarding maternal age, parity, or site of study (Table 1).
For the intention to treat group (ITT) detachment of
placentafollowingsublingualadministrationofnitroglycerin
occurred in 36.4% of the women compared to 23.2% in
the placebo group (P = 0.13) (Table 2). The corresponding
results for patients per protocol group (PP) were 37.3%
and 20.4% (P = 0.056), respectively (Table 3). In the two
hospitals with some experience of the method placenta was
successfully removed in 9 of 19 (47.4%) women following
treatment with nitroglycerin compared to 3 of 17 (15.0%)
women in the placebo group. The diﬀerence between the
treatment groups was 32.4% (95% CI −0.5; 58.8).
A signiﬁcant diﬀerence in blood pressure as well as pulse
rate between the nitroglycerin group and the placebo was
registered at 5 and 15 minutes after administration of tablets
(Figure 1). Maximum drop in blood pressure was measured
5 minutes after nitroglycerin had been given. However,
in all women who received nitroglycerin hemodynamic
changes were moderate and considered not to be of clinical
importance. There was no diﬀerence between the groups
regarding total blood loss or blood loss more than 1000 mL.
No complications of clinical importance due to nitroglycerin
were registered.
Headache and palpitations were relatively common in
both groups (Table 4). However, reported maternal side
eﬀects were only of minimal or moderate intensity with a
maximum of 6 on a VAS scale from 1 to 10. No statistical
diﬀerence was registered between the two groups regarding
frequency of side eﬀects or intensity of side eﬀects.
4. Discussion
In the present study successful release of placenta occurred
in 37.3% of the women with retained placenta following
sequential administration of oxytocin and nitroglycerin.
The corresponding ﬁgure in the two hospitals with some
experience of the method was 47.4%. Although none of
these ﬁgures reached statistical signiﬁcance compared to
placebo, the higher success rate in the two hospitals with
some experience could indicate that clinical experience is of
importance in order to achieve placental detachment.
Several descriptive and retrospective studies have exam-
ined the use of nitroglycerin for the release of retained
placenta [7, 10–14]. However, only one randomized study
has previously evaluated the eﬃciency of sequential admin-
Table 1: Demographic and baseline characteristics (intention to
treat group, ITT).
Variable Nitroglycerin
(n = 55)
Placebo
(n = 56)
P value
Age (years)
0.98 Mean (SD) 31.7 (5.0) 31.7 (5.6)
Median (range) 32 (19; 42) 32 (20; 44)
Parity n (%)
0.77
1 23 (41.8) 24 (42.9)
2 20 (36.4) 22 (39.3)
3 10 (18.2) 7 (12.5)
4 0 (0.0) 2 (3.6)
5 2 (3.6) 1 (1.8)
Site n (%)
1.00
A 11 (20.0) 11 (19.6)
B 13 (23.6) 14 (25.0)
C 7 (12.7) 8 (14.3)
D 17 (30.9) 17 (30.4)
E 7 (12.7) 6 (10.7)
Blood loss before
treatment (mL)∗ n = 53 n = 54
0.94
Mean (SD) 554 (464) 548 (457)
Median (range) 450 (50; 2400) 450 (0; 2000)
Time from delivery
0.06
to administration of
nitroglycerin or
placebo tablets
(minutes)∗
Mean (SD) 49.5 (8.9) 46.3 (7.5)
Median (range) 50 (27; 70) 46 (31; 62)
Intention to treat group, ITT: all randomized patients, including 4 patients
who did not receive study medication and 2 patients who only received
0.5mg nitroglycerin. ∗Four patients who did not receive study medication
are not included.
istration of oxytocin intravenously and nitroglycerin tablets
[6]. In that study, retained placenta was successfully released
in all 12 women following administration of nitroglycerin
c o m p a r e dt oo n l y1o f1 2w o m e ni nt h ep l a c e b og r o u p[ 6].
In addition, in a chart review of 24 women with retained pla-
centa,successfuldeliveryoftheplacentaoccurredin21ofthe
women following sequential treatment with intravenously
administered oxytocin and 1mg of nitroglycerin tablets
administered sublingually [7]. However, in both studies only
obstetricians who were experienced in the method were
involved in the attempts to remove the placenta. Thus, it
seems likely that clinical experience is essential in order to
accomplish a high success rate.
Three main causes of retained placenta have been
identiﬁed: (1) placenta adherens (81%); (2) trapped placenta
(13%); partial placenta accreta (6%) [15]. Placenta adherens
is due to inadequate myometrial contractions to separate the
placenta [3]. Trapped placenta signiﬁes a detached placenta
that is trapped behind a closed uterine cervix, while placenta
accreta indicates that an area of the placenta is ﬁrmly4 Obstetrics and Gynecology International
Table 2: Clinical data for management of retained placenta by treatment group (ITT).
Variable Nitroglycerin (n = 55) Placebo (n = 56) P value Relative risk (RR) 95% CI
Placental detachment
n (%) 20 (36.4) 13 (23.2) 0.13 1.57 (0.87; 2.83)
Blood loss after treatment (mL) n = 51 n = 54
Mean (SD) 465 (463) 560 (468)
0.30
Median (range) 250 (50; 2200) 400 (0; 1800)
Total blood loss (mL) n = 51 n = 54
Mean (SD) 1018 (612) 1098 (658)
0.52
Median (range) 900 (200; 2500) 950 (150; 3000)
Total blood loss ≥1000mL
n (%) 24 (43.6) 26 (46.4) 0.77 0.94 (0.62; 1.42)
Intention to treat group, ITT: all randomized patients, including 4 patients who did not receive study medication and 2 patients who only received 0.5mg
nitroglycerin.
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Figure 1: Systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse rate (PR) at baseline, 5 and 15 minutes after
administration of either nitroglycerin or placebo tablets. All parameters showed diﬀerences of statistical signiﬁcance between the groups
(P<0.05) following administration of the tablets.Obstetrics and Gynecology International 5
Table 3: Clinical data for management of retained placenta by treatment group (per protocol population, PP).
Variable Nitroglycerin (n = 51) Placebo (n = 54) P-value Relative Risk (RR) 95% CI
Placental detachment
n (%) 19 (37.3) 11 (20.4) 0.056 1.83 (0.97; 3.46)
Blood loss after treatment (mL) n = 48 n = 53
Mean (SD) 474 (470) 569 (468)
0.31 Median (range) 250.0 (50; 2200) 400 (0; 1800)
Total blood loss (mL) n = 48 n = 53
Mean (SD) 1020 (604) 1091 (662)
0.58 Median (range) 925 (200; 2500) 950 (150; 3000)
Total blood loss ≥1000mL
n (%) 23 (45.1) 25 (46.3) 0.90 0.97 (0.64; 1.48)
Per protocol population (PP): randomized patients who all received 1mg nitroglycerin or placebo tablets.
Table 4: Maternal side eﬀects following medical treatment (ITT
group).
Side eﬀect Nitroglycerin
(n = 55) Placebo (n = 56) P value
Headache (VAS
scale 1–10) n = 34 n = 33
Mean (SD) 0.9 (1.6) 0.5 (1.3)
0.08 Median (range) 0.0 (0; 6) 0.0 (0; 6)
Palpitations (VAS
scale 1–10) n = 29 n = 32
Mean (SD) 0.4 (1.1) 0.2 (0.5)
0.36 Median (range) 0.0 (0; 5) 0.0 (0; 2)
Intention to treat group, ITT: all randomized patients, including 4 patients
who did not receive study medication and 2 patients who only received
0.5mg nitroglycerin.
attached to the myometrium [15]. In the present study
ultrasonography was not performed routinely to distinguish
between the diﬀerent types of retained placenta. However,
none of the women was diagnosed with placenta accreta.
A signiﬁcant drop in both systolic and diastolic blood
pressure as well as a signiﬁcant increase in pulse rate was
registered following administration of nitroglycerin (Figure
1). However, in all women the hemodynamic eﬀects were
transient and nitroglycerin-induced uterine relaxation did
not aggravate vaginal hemorrhage. These ﬁndings conﬁrm
previous studies which have shown that sublingual admin-
istration of 1mg nitroglycerin in women with retained
placenta and normal blood loss is a safe procedure [6, 7].
Many of the women reported side eﬀects, especially
headache and palpitations of mild or moderate intensity
(Table 4). However, no statistical diﬀerence was registered
regarding frequency and intensity of side eﬀects between the
nitroglycerin and the placebo group. The high number of
reported side eﬀects may be due to the fact that the women
were informed about possible adverse eﬀects of nitroglycerin
before giving informed consent.
Sequential treatment with oxytocin and nitroglycerin
is supposed to initiate uterine contractions followed by
transient uterine relaxation, thereby promoting placental
detachment. In the present study three factors that could
possibly aﬀect the outcome of the method negatively were
identiﬁed following discussions with midwives and cross-
checking of the medical records: (1) oxytocin infusion
in the third stage was continued after administration of
nitroglycerin; (2) breastfeeding of the newborn child/nipple
stimulation was continued after administration of nitroglyc-
erin;(3)abdominaluterinemassagetopromotecontractions
was performed after administration of nitroglycerin. Clearly,
all these factors could possibly counteract the relaxing eﬀect
of nitroglycerin.
One weakness of the present study is that only obste-
tricians with no experience of the method were involved in
the study. On the other hand, the study describes a real-life
clinical scenario when a new method is being introduced.
It was simply not possible to carry out a multicenter study
involving only obstetricians with great experience of the
method. The fact that placenta was removed in almost
half of the women following administration of nitroglycerin
in the two hospitals with some experience of the method
is encouraging. Clearly, a large prospective randomized
placebo-controlled study performed by obstetricians who
have experience of the method would be of interest.
5. Conclusion
This study showed an increased release of retained placenta
following sequential administration of oxytocin and nitro-
glycerin compared to oxytocin and placebo. However, the
diﬀerenceinsuccessratedidnotreachstatisticalsigniﬁcance.
A tendency that clinical experience of the method could
be of importance for removal of placenta was registered.
Nitroglycerin did not cause any adverse eﬀects of clinical
importance.
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